Please use this identifier to cite or link to this item: http://nopr.niscair.res.in/handle/123456789/12623
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBhatta, Archita-
dc.date.accessioned2011-09-06T04:52:15Z-
dc.date.available2011-09-06T04:52:15Z-
dc.date.issued2011-09-
dc.identifier.issn0036-8512-
dc.identifier.urihttp://hdl.handle.net/123456789/12623-
dc.description23-25en_US
dc.description.abstractThe TRIPS agreement has not been able to deliver the benefits promised to developing countries, which now need to plan ways to ensure that strict IP regimes do not become a tool for pharma companies in developed countries to milk the poor in the developing world.en_US
dc.language.isoen_USen_US
dc.publisherNISCAIR-CSIR, Indiaen_US
dc.rights CC Attribution-Noncommercial-No Derivative Works 2.5 Indiaen_US
dc.sourceSR Vol.48(09) [September 2011]en_US
dc.titleTRIPS—Fifteen Years and Afteren_US
dc.typeArticleen_US
Appears in Collections:SR Vol.48(09) [September 2011]

Files in This Item:
File Description SizeFormat 
SR 48(9) 23-25.pdf537.81 kBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.